Mark Hamblin, MD
Internal Medicine · Kansas City, KSNPI 1588758502
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $95,360 of the $147,063 with a category attached, or 64.8%. Boehringer Ingelheim accounts for 92.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $47,931 and has fallen 52.4% since, to $22,827 in 2025. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $1176.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$136K
- Genentech USA, Inc.$4K
- United Therapeutics Corporation$2K
- Boehringer Ingelheim International GmbH$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Eli Lilly$500
- plus $387 from 5 others
Across 442 payments — averaging $11,333 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$2.1M
- Boehringer Ingelheim$1.5M
- Roche Products Limited$835K
- Cumberland Pharmaceuticals, Inc.$119K
- CSL Behring$102K
- Biogen$84K
- plus $262K from 7 others
What the payments were for
- Consulting fees$40,08527%
- Speaking & faculty fees$95,36065%
- Travel & lodging$8,3956%
- Food & beverage$3,2222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 100 | $135,665 |
| Genentech USA, Inc. | 3 | $4,372 |
| United Therapeutics Corporation | 8 | $2,130 |
| Boehringer Ingelheim International GmbH | 5 | $2,083 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,925 |
| Eli Lilly | 1 | $500 |
| ANI Pharmaceuticals, Inc. | 2 | $232 |
| Genentech, Inc. | 1 | $97 |
| Insmed, Inc. | 2 | $32 |
| Shire North American Group Inc | 1 | $14 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$69,401
- Esbriet$4,254
- PURIFIED CORTROPHIN GEL$209
- TYVASO$119
How this compares
$147,063 in reported general payments places this provider in the 95th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 428 | $5,212,367 |
| Pirfenidone | 136 | $180,828 |
| EsbrietPirfenidone | 17 | $154,684 |
| Humira(Cf) PenAdalimumab | 20 | $125,706 |
| Humira PenAdalimumab | 14 | $95,362 |
| Dupixent PenDupilumab | 14 | $52,389 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $46,679 |
| Mycophenolate Mofetil | 268 | $23,534 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $21,462 |
| Danazol | 29 | $11,746 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $8,992 |
| Qvar RedihalerBeclomethasone Dipropionate | 21 | $7,111 |
| Azathioprine | 76 | $5,384 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $4,580 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $135,665 | $5,221,359447 claims |
| Genentech USA, Inc.Esbriet | $4,372 | $154,68417 claims |
| AstraZenecaBevespi Aerosphere | $12 | $4,58013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Kansas City
- Shadi HamdehKansas City$959K
- Lucas PittsKansas City$235K
- Aaron RohrKansas City$54K
- Leslie SpikesKansas City$7K
- Alanna LeeKansas City$4K
- Donna GriebelLawrence$781K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.